Zobrazeno 1 - 5
of 5
pro vyhledávání: '"міфепристон"'
Publikováno v:
Репродуктивне здоров'я жінки; № 9-10 (2021); 94-99
Reproductive health of woman; № 9-10 (2021); 94-99
Reproductive health of woman; No. 9-10 (2021); 94-99
Reproductive health of woman; № 9-10 (2021); 94-99
Reproductive health of woman; No. 9-10 (2021); 94-99
The objective: to conduct a comparative analysis of the efficacy and tolerability of antigestagens (mifepristone) and gonadotropin-releasing hormone agonists (aGnRH) as part of adjuvant therapy for the prevention of the recurrence of uterine fibroids
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=scientific_p::39934e2f00538368b08dc46bf8a22f2e
http://repro-health.com.ua/article/view/252601
http://repro-health.com.ua/article/view/252601
Publikováno v:
Bukovinian Medical Herald; Vol. 25 No. 3 (99) (2021); 132-137
Буковинский медицинский вестник; Том 25 № 3 (99) (2021); 132-137
Буковинський медичний вісник; Том 25 № 3 (99) (2021); 132-137
Буковинский медицинский вестник; Том 25 № 3 (99) (2021); 132-137
Буковинський медичний вісник; Том 25 № 3 (99) (2021); 132-137
The purpose of the work. To study the effectiveness of the combined treatment of uterine leiomyoma (UL), taking into account the possibility of realizing reproductive function.Material and methods. The total number of women of reproductive age examin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=scientific_p::4c13b11e563d2f1eac5264ebbf11d643
http://e-bmv.bsmu.edu.ua/article/view/245071
http://e-bmv.bsmu.edu.ua/article/view/245071
Publikováno v:
Репродуктивне здоров'я жінки; № 3 (2021); 81-86
Reproductive health of woman; № 3 (2021); 81-86
Reproductive health of woman; No. 3 (2021); 81-86
Reproductive health of woman; № 3 (2021); 81-86
Reproductive health of woman; No. 3 (2021); 81-86
The objective: to determine the association of estrogen receptor gene polymorphisms ESR1 and progesterone PGR with the development of uterine leiomyoma (UL) and to develop a patient management algorithm based on the results of ultrasound and genetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=scientific_p::d7a1b9d6691ac3c04294dbd36f497087
http://repro-health.com.ua/article/view/234256
http://repro-health.com.ua/article/view/234256
Publikováno v:
Reproductive Endocrinology; № 54 (2020); 27-31
Репродуктивная эндокринология; № 54 (2020); 27-31
Репродуктивна ендокринологія; № 54 (2020); 27-31
Репродуктивная эндокринология; № 54 (2020); 27-31
Репродуктивна ендокринологія; № 54 (2020); 27-31
Objective of the study was to determine the characteristics of hormonal homeostasis in women with uterine leiomyoma in the course of treatment.Materials and methods. The hormonal status of 60 women with uterine leiomyoma at the age of 26–45 years w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=scientific_p::bb513f69a2cb91f1b0d3f84517dac8ef
http://reproduct-endo.com/article/view/214772
http://reproduct-endo.com/article/view/214772
Publikováno v:
Репродуктивна ендокринологія; № 39 (2018); 55-58
Репродуктивная эндокринология; № 39 (2018); 55-58
Reproductive Endocrinology; № 39 (2018); 55-58
Репродуктивная эндокринология; № 39 (2018); 55-58
Reproductive Endocrinology; № 39 (2018); 55-58
The article deals modern approaches used of mifepristone in order to prepare the cervix for delivery. The results of a study of 222 patients in the gestation period of 37–42 gestation weeks which given orally administered 200 mg of mifepristone at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=scientific_p::7af0e3ae48c0c8afee97a404f7d28990
http://reproduct-endo.com/article/view/128317
http://reproduct-endo.com/article/view/128317